HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 03, March 2019 – Driven by curiosity — Exclusive interview with Nobel laureate Ada Yonath: Her journey in science wasn't always crystal clear       » Your eyes don't deceive you, your brain does       » Organ donations to be computerised in China       » Over One tenth of Chinese people have mental health problems       » AI system can diagnose childhood diseases like doctors       » Bitter rapeseed potential protein source for human nutrition      
INSIDE INDUSTRY
New early breast cancer drug available in Singapore via special access program
Specialised Therapeutics Asia to make NERLYNX (neratinib) available to women in Singapore

A new breast cancer drug shown to significantly reduce the risk of cancer recurrence is now available to women in Singapore via a special access program.

The drug, NERLYNX (neratinib) is an oral medication taken by women with HER2+ early breast cancer who have completed adjuvant trastuzumab-based therapy. Neratinib is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4.

Five-year follow up data showed the drug reduced risk of invasive disease recurrence or death by 42 percent in women with early stage HER2+/HR+ (hormone-receptor positive) breast cancer.

In these patients, invasive disease-free survival (iDFS) was 90.8 percent in the patients treated with neratinib, compared with 85.7 percent in those receiving placebo.

NERLYNX is made available in Singapore by Specialised Therapeutics Asia, under exclusive license from Puma Biotechnology. The drug is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and was not expected to be approved by the Singapore Health Sciences Authority (HSA) before 2020.

Breast cancer is the most common cancer in women in Singapore, accounting for almost 30 percent of all cancer cases. Therefore, it is critical that women in Singapore who have recently completed adjuvant trastuzumab-based therapy or are about to complete adjuvant trastuzumab-based therapy, are provided access to NERLYNX now, as the greatest benefit is seen in women who commence therapy as soon as possible.

Click here for the complete issue.

NEWS CRUNCH  
news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy